[EmeraNova™ (BusinessWire)] EmeraNova^TM is expanding its tissue preparation and restorative capabilities through a new commercialization collaboration with Hyalomatrix^®, a regenerative matrix built on hyaluronic acid technology to support tissue regeneration and complex wound healing.

[Pilatus Biosciences] Pilatus Biosciences announced that the first patient has been dosed in Hong Kong, in the hepatocellular carcinoma biomarker backfill cohort of its ongoing Phase I clinical trial of PLT012, a monoclonal antibody targeting CD36, a key regulator of lipid metabolism within the tumor microenvironment.

[Calluna Pharma] Calluna Pharma announced completion of dosing in the Phase II AURORA study of CAL101 in idiopathic pulmonary fibrosis, a monoclonal antibody designed to neutralize extracellular S100A4, involved in inflammatory, and fibrotic signaling.

[Immunity] The authors identified microglia-mediated extracellular matrix disruption as a driver of brain dysfunction following alcohol abuse and MyD88 as a critical therapeutic target for alcohol use disorder.

[Signal Transduction and Targeted Therapy] Through integrated single-cell and spatial transcriptomic profiling across four cancer types, researchers identified two distinct immunomodulatory cancer-associated fibroblast (CAF) states, termed antigen-presenting CAFs, and matrix-producing CAFs.

[Advanced Science] Scientists identified focal adhesion kinase (FAK/PTK2) as a central mechanobiological regulator that couples ECM remodeling with cellular mechanics to control nanoparticle transport and cellular uptake.

[Science Advances] Investigators engineered an armored chimeric antigen receptor (CAR) T cell platform that locally targets the extracellular matrix by secreting a tenascin-C-specific single-chain variable fragment linked to conventional CAR architecture.

[Science Advances] The authors introduced dynamic network regulation of cell-matrix interactions via photochemical control in a synthetic and fibrous highly biomimetic hydrogel.

[Advanced Healthcare Materials] Scientists designed biomimetic viscoelastic hyaluronan-based hydrogels to understand the effect of viscoelasticity on the invasion of heterogeneous glioblastoma stem cells within the brain ECM.

[Acta Biomaterialia] Investigators imaged fibrillar ECM components across layers of healthy and hypertensive arteries in a large animal model and quantified their stiffness with submicron and piconewton resolution.

[ACS Applied Materials & Interfaces] Researchers reported a sequential dual-nanoparticle approach that integrates ECM remodeling with tumor-targeted chemotherapy to overcome the insufficient tumor targeting and poor intratumoral penetration of liposomal doxorubicin.

[Journal of Dental Research] The authors investigated whether ECM remodeling represents a quantifiable feature of fanconi anemia-associated oral potentially malignant disorders.